Clinical trial
Observational Study of Zongertinib in Patients With HER2-mutated NSCLC in Japan (J-HERZ)
NCT07926308 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Observational Study of Zongertinib in Patients With HER2-mutated NSCLC in Japan (J-HERZ)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 17, 2026
- Completion date
- December 31, 2031
- Enrollment
- 300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer
Arms
As registered; 3 arms.
-
Zongertinib first-line treatment (1L) group
Japanese patients with human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC) have received their first systemic anticancer therapy for metastatic or locally advanced NSCLC.
-
Zongertinib second-line treatment (2L) group
Japanese patients with HER2-mutated NSCLC have received their systemic anticancer therapy administered after one prior line of systemic therapy for metastatic or locally advanced NSCLC.
-
Zongertinib third-line treatment (3L) group
Japanese patients with HER2-mutated NSCLC have received their systemic anticancer therapy administered after two prior lines of systemic therapy for metastatic or locally advanced NSCLC.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Real-world overall response rate (rwORR) in the zongertinib 1L group
Lead sponsor's other trials
Boehringer Ingelheim, most recent start first.
+2,298 more trials See the organization page
Similar trials
Same condition (Carcinoma, Non-Small-Cell Lung) and phase, most recent start first.
+1,112 more trials See the condition page